| Literature DB >> 28304141 |
Martin L Kårhus1, Andreas Brønden1, David P Sonne1,2, Tina Vilsbøll1,3,4, Fillip K Knop1,3,5.
Abstract
Bile acids are amphipathic water-soluble steroid-based molecules best known for their important lipid-solubilizing role in the assimilation of fat. Recently, bile acids have emerged as metabolic integrators with glucose-lowering potential. Among a variety of gluco-metabolic effects, bile acids have been demonstrated to modulate the secretion of the gut-derived incretin hormone glucagon-like peptide-1 (GLP-1), possibly via the transmembrane receptor Takeda G-protein-coupled receptor 5 and the nuclear farnesoid X receptor, in intestinal L cells. The present article critically reviews current evidence connecting established glucose-lowering drugs to bile acid-induced GLP-1 secretion, and discusses whether bile acid-induced GLP-1 secretion may constitute a new basis for understanding how metformin, inhibitors of the apical sodium-dependent bile acids transporter, and bile acid sequestrants - old, new and neglected glucose-lowering drugs - improve glucose metabolism.Entities:
Keywords: zzm321990GLP-1; ASBT inhibitors, bile acid, bile acid sequestrants, drug mechanism; antidiabetic drug; incretin therapy; metformin; type 2 diabetes
Mesh:
Substances:
Year: 2017 PMID: 28304141 DOI: 10.1111/dom.12946
Source DB: PubMed Journal: Diabetes Obes Metab ISSN: 1462-8902 Impact factor: 6.577